Tirzepatide’s Glowing Obesity Data Steal Show On Lilly’s Earnings Call
Executive Summary
Tirzepatide shows ability to produce a mean 52-pound weight loss at 72 weeks, setting up a market showdown with Novo’s Wegovy. Lilly’s quarterly call included reassurance about donanemab for Alzheimer’s and high growth for its COVID-19 antibody.
You may also be interested in...
The Next Frontier In Obesity: Better, Not More, Weight Loss
R&D leaders from Novo Nordisk, Lilly, Boehringer Ingelheim and others discussed what some of the advances could be in the next generation of obesity medicines.
With Competition Closing In, Novo Details Oral Semaglutide Weight Loss At ADA
Novo’s oral semaglutide generated 15.1% weight loss at 68 weeks in the Phase IIIa OASIS 1 study, but Lilly’s orforglipron provided up to 14.7% weight loss at 36 weeks in Phase II without reaching a plateau.
Lilly’s Mounjaro Shows Strong Sales And Data As Firm Eyes Obesity Market
Excluding COVID-19 antibodies, the company said revenues for the quarter increased by 10% while volume increased by 18%, and sales of Mounjaro came in stronger than analysts anticipated.